BLA 761369 · Pfizer INC
Hympavzi
Marstacimab-Hncq · Subcutaneous
NovelOrphanCDER novel approval, Oct 11, 2024: To prevent or reduce bleeding episodes related to hemophilia A or B
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Oct 11, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
10
4 Phase 3, 7 recruiting
FAERS reports
103
55 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: THROMBOEMBOLIC EVENTS • Venous and arterial thromboembolic events were reported in patients treated with HYMPAVZI with thrombotic risk factors [see Warnings and Precautions (5.1) ] . • Monitor patients for signs or symptoms of thromboembolism and interrupt use of HYMPAVZI if these occur and manage as clinically indicated [see Warnings and Precautions (5.1) ] . WARNING: THROMBOEMBOLIC EVENTS See full prescribing information for complete boxed warning. • Venous and arterial thromboembolic events were reported in patients treated with HYMPAVZI with thrombotic risk factors. ( 5.1 ) • Monitor patients for signs or symptoms of thromboembolism and interrupt use of HYMPAVZI if these occur and manage as clinically indicated. ( 5.1 )
What it is approved for
From the label in effect Nov 13, 2026.
HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with: • hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or • hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors. HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with: • hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or • hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors. ( 1 )
Mechanism: Marstacimab‑hncq is a human monoclonal IgG1 antibody directed against the Kunitz domain 2 (K2) of TFPI to neutralize TFPI activity and enhance coagulation. TFPI is the primary inhibitor of the extrinsic coagulation cascade and negatively regulates thrombin generation within the extrinsic pathway of coagulation by inactivating the protease functions of FXa/FVIIa/TF complex. TFPI binds to and inhibits the factor Xa active site via its second Kunitz inhibitor domain (K2).
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 5, 2026 Supplement 3 · Efficacy · priority review OrphanLetterLabel
- Oct 11, 2024 Original approval · Type 1 - New Molecular Entity NovelOrphanLetterLabelReview
1 products under this application
- HYMPAVZI · MARSTACIMAB-HNCQ 300MG · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Marstacimab" as an intervention, any sponsor and status, largest first.
- Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT05145127 · 245 participants (planned) · Start Nov 17, 2021 · Primary completion Jul 31, 2030
Drug: PF-06741086 · For: Hemophilia A; Hemophilia B
Sites: Iowa City, Iowa; New Hyde Park, New York; Philadelphia, Pennsylvania · 78 sites in all
- Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia BPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03938792 · 188 participants · Start Mar 9, 2020 · Primary completion Apr 29, 2025
Drug: PF-06741086 · For: Hemophilia A; Hemophilia B
Sites: Tampa, Florida; Iowa City, Iowa; New Hyde Park, New York · 62 sites in all
- A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT05611801 · 100 participants (planned) · Start Dec 9, 2022 · Primary completion Sep 10, 2028
Drug: marstacimab · For: Hemophilia A; Hemophilia B
Sites: Salt Lake City, Utah; Mendoza, Argentina; Parkville, Australia · 62 sites in all
- A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without InhibitorsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07923981 · 95 participants (planned) · Start Oct 23, 2026 · Primary completion Jul 2, 2029
Drug: marstacimab · For: Hemophilia A or B
Sites: Flowood, Mississippi
PfizerPfizer (PFE)
NCT02531815 · 41 participants · Start Aug 2015 · Primary completion Jul 2016
Drug: PF-06741086; Placebo · For: Healthy
Sites: Brussels, Belgium
PfizerPfizer (PFE)
NCT02974855 · 27 participants · Start Mar 8, 2017 · Primary completion Dec 3, 2018
Drug: PF-06741086; PF-06741086 and 2 more · For: Hemophilia A or B
Sites: Aurora, Colorado; Chicago, Illinois; Santiago, Chile · 10 sites in all
- A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) DeviceTerminated
PfizerPfizer (PFE)
NCT04832139 · 22 participants · Start Mar 30, 2021 · Primary completion Nov 22, 2021
Drug: Marstacimab PFP; Marstacimab PFS · For: Healthy Volunteers
Sites: Brussels, Belgium
PfizerPfizer (PFE)
NCT03363321 · 20 participants · Start May 30, 2018 · Primary completion Aug 5, 2020
Drug: PF-06741086 · For: Hemophilia A or B
Sites: Aurora, Colorado; Campinas, Brazil; Santiago, Chile · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- haemarthrosis21
- haemorrhage18
- drug dose omission by device9
- device defective7
- device failure6
- epistaxis6
- contusion5
- arthralgia4
- device malfunction4
- drug ineffective4
- joint swelling4
- product dose omission issue4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 5 |
| 2025 | 34 |
| 2026 | 64 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial.
Matino D, Palladino A, Taylor CT, et al. · Blood 2025 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial.
Matino D, Acharya SS, Taylor CT, et al. · Blood 2026 · Clinical Trial, Phase III, Multicenter Study
- A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia.
Mahlangu JN, Lamas JL, Morales JC, et al. · Br J Haematol 2023 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Management of breakthrough bleeds and surgical procedures in participants with hemophilia A or B without inhibitors receiving marstacimab prophylaxis in the phase 3 BASIS study.
Mahlangu J, Matino D, Benítez Hidalgo O, et al. · J Thromb Haemost 2026 · Clinical Trial, Phase III, Multicenter Study
- Safety and efficacy of marstacimab in patients with hemophilia A and B: a systematic review and meta-analysis.
Mokresh ME, Alomari O, Mokresh S, et al. · Expert Rev Hematol 2025 · Systematic Review, Meta-Analysis
- Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results.
Mahlangu J, Luis Lamas J, Cristobal Morales J, et al. · Br J Haematol 2023 · Multicenter Study, Clinical Trial, Phase II
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.